Results 201 to 210 of about 79,111 (213)

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

New England Journal of Medicine, 2001
exaly  

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

New England Journal of Medicine, 2001
exaly  

Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin‐converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Added trial

European Journal of Heart Failure, 2008
Christopher B Granger, Salim Yusuf, Karl Swedberg   +2 more
exaly  

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

Lancet, The, 2010
exaly  

Effects of angiotensin II receptor blockers on insulin resistance

Hypertension Research, 2010
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

2007
openaire   +1 more source

[Organ protection by angiotensin II receptor blockers].

Nihon rinsho. Japanese journal of clinical medicine, 2004
Hiroo, Kumagai, Toshiko, Onami, Chie, Takimoto, Kamon, Iigaya, Takao, Saruta   +4 more
openaire   +1 more source

Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

Clinical Therapeutics, 2011
exaly  

[Metabolic effects of angiotensin-II receptor blockers].

Kardiologiia, 2003
R G, Oganov, D V, Nebieridze
openaire   +1 more source

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Lancet, The, 2005
exaly